The Complete Guide to
Bioprocessing
From upstream cell culture to downstream purification — everything you need to understand modern bioprocessing, single-use technology, and why industry leaders are making the shift to flexible, single-use systems.
What is Bioprocessing?
Bioprocessing is the production of a value-added material from a living source. The defining characteristic is that the source organism is alive and actively responsive to its environment.
Because the organism will adjust its physiology to maximize efficiency in response to changes in its physico-chemical environment, this translates to potential variability in the nature of the product.
Unlike purely chemical synthesis, bioprocessing harnesses the metabolic machinery of living cells to produce complex molecules — proteins, antibodies, enzymes, vaccines — that would be impossible or prohibitively expensive to synthesize by conventional chemistry.
What is the Purpose of Bioprocessing?
The archetypical bioprocess is based on growing organisms — viral, bacterial, fungal, mammalian, human, insect, or plant cells — that have been genetically modified to produce a commercially valuable product at scale.
Monoclonal antibodies, vaccines, hormones, and recombinant proteins produced at scale for therapeutic use in patients worldwide.
Food-grade enzymes, nutritional supplements, probiotics, amino acids, and fermented food ingredients for human and animal health.
Ethanol, biodiesel, and other renewable energy sources — plus beverages like beer, wine, and kombucha — generated through microbial fermentation.
The product is, by definition, of limited or no value to the producing organism — it is either excreted or stored internally. Effectively the organism is tricked into producing something mankind needs but it does not.
Stages of Bioprocessing
For the production of a therapeutic drug product, bioprocessing is divided into two fundamental stages. The number of steps involved can vary significantly depending on the product and organism.
Cell Culture & Growth
The upstream process spans everything from early cell isolation and cultivation through cell banking, culture expansion, and final harvest. Cells grow in bioreactors (mammalian) or fermenters (bacterial), starting small-scale and scaling up incrementally.
- 1Cell isolation & early cultivation
- 2Cell banking & cryopreservation
- 3Inoculum development & media formulation
- 4Genetic enhancement & optimization
- 5Culture scale-up & expansion
- 6Harvest of live cell batch
Purification & Recovery
Downstream processing takes cell mass from upstream and processes it to meet purity and quality requirements. It is divided into three core sections: cell disruption, purification, and polishing.
- 1Biomass separation — centrifugation, ultra-centrifugation, or filtration
- 2Cell disruption — mechanical (bead milling) or non-mechanical (enzymes, sonication)
- 3Concentration — tangential flow filtration (TFF)
- 4Purification — chromatography, TFF, buffer exchange steps
- 5Polishing — removal of host cell proteins, DNA, viruses, endotoxins
Types of Bioprocessing
There are 3 principal types of cell culture processes used in upstream processing. Each has distinct operational characteristics, and the right choice depends on your product, scale, and schedule.
In a batch culture, after inoculation of cells and media there is no addition or removal of broth components until the end of fermentation. The only exchanges are gas, buffer, and anti-foam if needed.
Initially cell count rises rapidly due to surplus nutrients. As nutrients are consumed, growth decreases until nutrient limitation becomes the rate-limiting step.
- Flexible scheduling; shorter fermentation cycles
- Versatile — easy to switch between cell processes
- Low contamination risk
- Complete substrate conversion
- High labor cost; automation is difficult
- Reactor downtime for CIP/SIP between batches
- Lower yields vs. fed-batch
A fed-batch starts as a standard batch but at a trigger point, media containing nutrients is fed incrementally. The broth volume grows and cells continue multiplying. This is the most widely used process mode in biopharma today.
Either the inlet or outlet pipe is open — but not both. Since adding feed is far more beneficial than removing cells, this is virtually always run as a feed-in mode.
- Controlled conditions via feed management
- High cell densities achievable
- Higher product yields than standard batch
- Low contamination risk; flexible scheduling
- Downstream must handle elevated cell densities
- Higher labor cost than continuous
- Longer culture times required
In continuous fermentation, both inlet and outlet pipes are open simultaneously at equal flow rates. The reactor volume remains constant throughout, enabling steady-state production for weeks or months.
Steady-state concentrations of cells and nutrients allow for predictable, consistent product quality — ideal for high-volume, commercial-scale campaigns.
- High productivity; product constantly generated
- Easy automation at consistent settings
- High capacity utilization efficiency
- Constant, predictable product quality
- Contamination risk grows with process duration
- Inflexible; maintenance must be pre-planned
- Cellular mutations may accumulate over time
- Downstream must also run continuously
Benefits of Single-Use Bioprocessing
Single-use technology has transformed biopharmaceutical manufacturing. From reducing capital expenditure to eliminating cross-contamination, here is why industry leaders are making the switch.
Complex CIP and SIP stages — and their associated labor costs — become void with single-use technologies. WFI water costs and cleaning chemical costs can be minimized or eliminated entirely.
Cleaning and validation between separate production stages can be eliminated. Downtime between operations can be significantly reduced, directly impacting facility utilization efficiency.
Single-use assemblies allow large reductions in media consumption. The average carbon footprint reduction — including water, energy, and chemicals — is approximately 40% versus stainless steel.
Single-use solutions render cross-contamination virtually impossible, since all product-contact surfaces are disposed of when each batch is transferred to the next manufacturing step.
Single-use systems arrive pre-assembled, pre-sterilized, and ready to use with full quality and validation packages. Responsibility for regulatory compliance moves from user to supplier.
Single-use equipment does not require elaborate cleaning before disposal. Plastic-based assemblies can be recycled or incinerated to recover stored chemical energy — far simpler than steel recycling.
Time previously spent on preparation and post-batch cleanup is freed for productive tasks, significantly increasing facility output per unit time and enabling more competitive product pricing.
Challenges in Bioprocessing
While single-use bioprocessing offers compelling advantages, practitioners must navigate technical, regulatory, and operational challenges. Foxx Life Sciences provides validated solutions across all of them.
Single-use processing has scale limitations versus stainless steel. However, increased titers are reducing bioreactor sizes needed, and the growth of personalized medicine is pushing down batch sizes — allowing single-use technology to meet requirements previously dominated by stainless steel.
Automation of single-use processes offers quality, safety, and productivity improvements — freeing operators for value-added tasks, controlling process variables, and automating data acquisition to 21 CFR Part 11 for cGMP batch record creation.
Product contact materials must comply with global regulatory standards. Non-standard materials can require additional testing. Selecting a validated component portfolio — such as Foxx's — can eliminate the need for extra validation entirely.
Creating a customized single-use assembly from concept to delivery can take months. Generating a configured assembly from a library of pre-validated components — as Foxx provides — offers significant reduction in design time and lead times.
Single-use assemblies must be leak-free and fault-free. As flexible polymeric materials cannot be high-pressure tested, standard procedures include visual inspection, low-pressure decay testing, and Quality by Design (QbD) methodology.
Extractables data has historically been generated with varied techniques, making vendor comparisons difficult. New industry guidelines are creating standardized materials and testing regimes that streamline validation and ease the path to regulatory compliance.
Partner with Foxx for
Every Stage of Your Workflow
From pre-validated single-use assemblies to fully custom SUT solutions — Foxx Life Sciences delivers ISO 13485–certified quality with the speed and flexibility your bioprocess demands.